Research programme: helicobacter pylori infection therapies - aRigen

Drug Profile

Research programme: helicobacter pylori infection therapies - aRigen

Alternative Names: ARH-1029

Latest Information Update: 02 Jul 2012

Price : $50

At a glance

  • Originator aRigen
  • Developer aRigen; Taiho Pharmaceutical
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Helicobacter infections

Most Recent Events

  • 13 May 2010 ARH 1029 licensed to CJ CheilJedang Corporation in South Korea
  • 23 Feb 2009 Preclinical development is ongoing in Japan
  • 14 Nov 2006 Preclinical trials in Helicobacter infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top